Shanghai, China
Genor BioPharma Co., Ltd., established in 2007, is an innovative biopharma company focusing on top oncology areas. With its headquarters in China, the company has garnered significant attention, having received a notable $160.00M Series B investment on 01 June 2020 from Temasek Holdings, Cavenham PE, Haitong Capital, Hillhouse Investment, CR-CP Life Science Fund.
Genor Biopharma's unique approach in creating a fully integrated and end-to-end biopharma innovation company sets it apart. The company's presence in San Francisco is notable, where its Antibody Therapeutics Inc. is at the forefront of bispecific and multi-specific discovery platforms, pioneering novel therapeutic antibody candidates through advanced technology and engineering.
Furthermore, the industry-leading R&D center in Shanghai focuses on CMC development, capable of comprehensive bioprocesses and formulations. The company's commercial facility in Yuxi, Yunan is equipped for commercial manufacturing, including Phase III and pivotal trial clinical supplies.
Currently, Genor Biopharma has 10+ drug candidates under development, highlighting its commitment to advancing therapeutic solutions. With Geptanolimab's (GB226) NDA granted for priority review and successful NDA pre-approval inspection, the company is poised for a product launch in 2021, with a focus on pioneering safe and high-quality therapeutic benefits for patients. The NDA filing for Infliximab (GB242) has also been accepted and is under review by the agency.
Genor BioPharma's strategic investments, innovative pipeline, and global reach position the company as a key player in the biopharma and pharmaceutical industries, showcasing potential for significant growth and impact in the oncology space.
